Sökning: onr:"swepub:oai:lup.lub.lu.se:d491b132-d3ed-4684-b038-89116f8e2ab9" >
An exploratory open...
An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocol
-
- Sagar, Rachel L (författare)
- University College London
-
- Åström, Eva (författare)
- Karolinska Institute
-
- Chitty, Lyn S (författare)
- Great Ormond Street Hospital
-
visa fler...
-
Crowe, Belinda (författare)
-
- David, Anna L (författare)
- University College London Hospital
-
DeVile, Catherine (författare)
-
- Forsmark, Annabelle (författare)
- PharmaLex Sweden AB
-
- Franzen, Vera (författare)
- XNK Therapeutics AB
-
- Hermerén, Göran (författare)
- Lund University,Lunds universitet,Medicinsk etik,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Ethics,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Hill, Melissa (författare)
-
- Johansson, Mats (författare)
- Lund University,Lunds universitet,Medicinsk etik,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Ethics,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Lindemans, Caroline (författare)
- University Medical Center Utrecht
-
- Lindgren, Peter (författare)
- Karolinska University Hospital
-
Nijhuis, Wouter (författare)
-
- Oepkes, Dick (författare)
- Leiden University Medical Centre
-
- Rehberg, Mirko (författare)
- University Hospital of Cologne
-
- Sahlin, Nils-Eric (författare)
- Lund University,Lunds universitet,Medicinsk etik,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Vetenskap och Beprövad Erfarenhet (VBE),Forskargrupper vid Lunds universitet,Medical Ethics,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,VBE,Lund University Research Groups
-
Sakkers, Ralph (författare)
-
Semler, O (författare)
-
- Sundin, Mikael (författare)
- Karolinska Institutet
-
Walther-Jallow, Lilian (författare)
-
Verweij, EJT Joanne (författare)
-
Westergren, Magnus (författare)
-
- Götherström, Cecilia (författare)
- Karolinska Institute
-
visa färre...
-
(creator_code:org_t)
- 2024
- 2024
- Engelska.
-
Ingår i: BMJ Open. - 2044-6055. ; 14:6
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction Severe osteogenesis imperfecta (OI) is a debilitating disease with no cure or sufficiently effective treatment. Mesenchymal stem cells (MSCs) have good safety profile, show promising effects and can form bone. The Boost Brittle Bones Before Birth (BOOSTB4) trial evaluates administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells) for OI type 3 or severe type 4.Methods and analysis BOOSTB4 is an exploratory, open-label, multiple dose, phase I/II clinical trial evaluating safety and efficacy of postnatal (n=15) or prenatal and postnatal (n=3, originally n=15) administration of BOOST cells for the treatment of severe OI compared with a combination of historical (1–5/subject) and untreated prospective controls (≤30). Infants<18 months of age (originally<12 months) and singleton pregnant women whose fetus has severe OI with confirmed glycine substitution in COL1A1 or COL1A2 can be included in the trial.Each subject receives four intravenous doses of 3×106/kg BOOST cells at 4 month intervals, with 48 (doses 1–2) or 24 (doses 3–4) hours in-patient follow-up, primary follow-up at 6 and 12 months after the last dose and long-term follow-up yearly until 10 years after the first dose. Prenatal subjects receive the first dose via ultrasound-guided injection into the umbilical vein within the fetal liver (16+0 to 35+6 weeks), and three doses postnatally.The primary outcome measures are safety and tolerability of repeated BOOST cell administration. The secondary outcome measures are number of fractures from baseline to primary and long-term follow-up, growth, change in bone mineral density, clinical OI status and biochemical bone turnover.Ethics and dissemination The trial is approved by Competent Authorities in Sweden, the UK and the Netherlands (postnatal only). Results from the trial will be disseminated via CTIS, ClinicalTrials.gov and in scientific open-access scientific journals.Trial registration numbers EudraCT 2015-003699-60, EUCT: 2023-504593-38-00, NCT03706482.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
-
BMJ Open
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Sagar, Rachel L
-
Åström, Eva
-
Chitty, Lyn S
-
Crowe, Belinda
-
David, Anna L
-
DeVile, Catherin ...
-
visa fler...
-
Forsmark, Annabe ...
-
Franzen, Vera
-
Hermerén, Göran
-
Hill, Melissa
-
Johansson, Mats
-
Lindemans, Carol ...
-
Lindgren, Peter
-
Nijhuis, Wouter
-
Oepkes, Dick
-
Rehberg, Mirko
-
Sahlin, Nils-Eri ...
-
Sakkers, Ralph
-
Semler, O
-
Sundin, Mikael
-
Walther-Jallow, ...
-
Verweij, EJT Joa ...
-
Westergren, Magn ...
-
Götherström, Cec ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Pediatrik
- Artiklar i publikationen
-
BMJ Open
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet